Frazier Life Sciences Management’s Edgewise Therapeutics EWTX Stock Holding History

Frazier Life Sciences Management’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,271,245	Closed	-$33.9M	–	53
2024 Q4	$33.9M	Sell	1,271,245 -1,561,622	-55%	-$49.7M	1.41%	18
2024 Q3	$75.6M	Sell	2,832,867 -898,200	-24%	-$17.9M	3.03%	12
2024 Q2	$67.2M	Buy	3,731,067 +427,500	+13%	+$7.46M	3.14%	11
2024 Q1	$60.3M	Buy	3,303,567 +636,364	+24%	+$10.1M	2.54%	12
2023 Q4	$29.2M	Buy	2,667,203 +1,818,181	+214%	+$12.8M	1.56%	16
2023 Q3	$4.86M	Buy	849,022 +100,000	+13%	+$680K	0.32%	44
2023 Q2	$5.8M	Buy	749,022 +66,561	+10%	+$561K	0.35%	38
2023 Q1	$4.55M	Buy	+682,461	New	+$6.33M	0.33%	44

Other funds holding EWTX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Frazier Life Sciences Management's EWTX Position: Q1 2025 in Review

Frazier Life Sciences Management sold out of Edgewise Therapeutics (EWTX) in Q1 2025, closing a stake of 1,271,245 shares — an estimated $33.9M sold.

Frazier Life Sciences Management first reported a position in EWTX in Q1 2023 and held it in 8 quarters. The position peaked at $75.6M in Q3 2024. 192 funds tracked by Wall St. Rank hold EWTX as of Q1 2025.

Frazier Life Sciences Management reported no remaining Edgewise Therapeutics position as of Q1 2025 after selling out during the quarter.
Frazier Life Sciences Management sold 1,271,245 Edgewise Therapeutics shares in Q1 2025, an estimated $33.9M.
Frazier Life Sciences Management first reported a position in Edgewise Therapeutics in Q1 2023 and held it in 8 quarters.
Frazier Life Sciences Management's Edgewise Therapeutics position peaked at $75.6M in Q3 2024.
192 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2025.

Based on Frazier Life Sciences Management's 13F filing for Q1 2025, filed 15 May 2025.